GlassScriptPhysician profile
Emitis Hosoda
NPI 1104994250
$3,336.45
in general payments reported to CMS, 2019-2025
29 companies · $441 in 2025
The $441 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $585 · 2021: $712 · 2022: $443 · 2023: $577 · 2024: $398 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,415.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $594.68 | 2019-2023 | Spiriva Respimat |
| Abbvie INC. | $354.05 | 2020-2025 | |
| Amgen INC. | $346.00 | 2020-2025 | Repatha, Otezla, Evenity |
| Abbott Laboratories | $228.77 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $227.34 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $203.87 | 2020-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.92 | 2022-2025 | Xifaxan, Trulance |
| Daiichi Sankyo INC. | $141.90 | 2019-2021 | |
| Novo Nordisk INC | $105.62 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $97.59 | 2020-2023 | Breztri |
| Paratek Pharmaceuticals, INC. | $97.31 | 2022-2025 | Nuzyra, Xhance |
| Ibsa Pharma INC. | $90.48 | 2021-2024 | Tirosint, Tirosint, Licart |
| Biohaven Pharmaceuticals, INC. | $90.04 | 2020-2021 | |
| Lilly USA, LLC | $84.50 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $73.82 | 2022-2023 | Quviviq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $69.57 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $64.11 | 2022 | |
| Alexion Pharmaceuticals, INC. | $49.95 | 2025 | Strensiq |
| Henry Schein, INC. | $43.02 | 2025 | |
| Medtronic, INC. | $34.90 | 2025 | Intellis Adaptivestim |
| Teva Pharmaceuticals USA, INC. | $31.15 | 2023 | Austedo |
| Viatris Specialty LLC | $24.29 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $24.24 | 2023 | Dificid |
| Bayer Healthcare Pharmaceuticals INC. | $21.39 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $21.35 | 2023 | Rexulti |
| Allergan, INC. | $19.71 | 2020 | |
| Azurity Pharmaceuticals, INC. | $19.24 | 2023 | Edarbi |
| Takeda Pharmaceuticals U.S.A., INC. | $15.88 | 2020 | |
| Rhythm Pharmaceuticals, INC. | $15.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emitis Hosoda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.